Allogene Therapeutics Inc (NASDAQ: ALLO)’s stock price has dropped by -5.29 in relation to previous closing price of 2.27. Nevertheless, the company has seen a loss of -30.42% in its stock price over the last five trading days. globenewswire.com reported 2024-11-18 that SOUTH SAN FRANCISCO, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced preclinical data for ALLO-329, an investigational allogeneic CD19/CD70 dual CAR T cell therapy being evaluated as a treatment for autoimmune diseases. The data, presented at the American College of Rheumatology (ACR) Convergence 2024, demonstrate the potential of ALLO-329 to specifically address key challenges associated with current autologous CAR T cell therapies in development for patients with autoimmune disease and highlights the promise of an allogeneic CAR T to reset the immune system.
Is It Worth Investing in Allogene Therapeutics Inc (NASDAQ: ALLO) Right Now?
Company’s 36-month beta value is 0.83.Analysts have differing opinions on the stock, with 9 analysts rating it as a “buy,” 4 as “overweight,” 5 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ALLO is 142.43M, and currently, short sellers hold a 26.01% ratio of that floaft. The average trading volume of ALLO on November 19, 2024 was 2.04M shares.
ALLO’s Market Performance
ALLO stock saw a decrease of -30.42% in the past week, with a monthly decline of -24.30% and a quarterly a decrease of -18.56%. The volatility ratio for the week is 9.69%, and the volatility levels for the last 30 days are 8.97% for Allogene Therapeutics Inc (ALLO). The simple moving average for the past 20 days is -21.75% for ALLO’s stock, with a -31.77% simple moving average for the past 200 days.
Analysts’ Opinion of ALLO
Many brokerage firms have already submitted their reports for ALLO stocks, with Oppenheimer repeating the rating for ALLO by listing it as a “Outperform.” The predicted price for ALLO in the upcoming period, according to Oppenheimer is $11 based on the research report published on August 08, 2024 of the current year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see ALLO reach a price target of $11. The rating they have provided for ALLO stocks is “Overweight” according to the report published on May 31st, 2024.
ALLO Trading at -21.64% from the 50-Day Moving Average
After a stumble in the market that brought ALLO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -62.77% of loss for the given period.
Volatility was left at 8.97%, however, over the last 30 days, the volatility rate increased by 9.69%, as shares sank -23.21% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -13.31% lower at present.
During the last 5 trading sessions, ALLO fell by -30.42%, which changed the moving average for the period of 200-days by -46.91% in comparison to the 20-day moving average, which settled at $2.75. In addition, Allogene Therapeutics Inc saw -33.02% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALLO starting from Parker Geoffrey M., who proposed sale 36,404 shares at the price of $2.84 back on Oct 21 ’24. After this action, Parker Geoffrey M. now owns shares of Allogene Therapeutics Inc, valued at $103,501 using the latest closing price.
Douglas Earl Martin, the Officer of Allogene Therapeutics Inc, proposed sale 28,310 shares at $2.79 during a trade that took place back on Aug 21 ’24, which means that Douglas Earl Martin is holding shares at $78,844 based on the most recent closing price.
Stock Fundamentals for ALLO
Current profitability levels for the company are sitting at:
- -6501.95 for the present operating margin
- -1437.6 for the gross margin
The net margin for Allogene Therapeutics Inc stands at -6591.37. The total capital return value is set at -0.5. Equity return is now at value -54.15, with -43.56 for asset returns.
Currently, EBITDA for the company is -300.29 million with net debt to EBITDA at -0.13. When we switch over and look at the enterprise to sales, we see a ratio of 11271.88. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.35.
Conclusion
In a nutshell, Allogene Therapeutics Inc (ALLO) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
